Exicure, Inc. (XCUR)
NCM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
EXICURE, INC. — 8-K Filing
# 🔥 What This Document Is This is a legal notice filed with the SEC to inform **Exicure, Inc. (XCUR)** stockholders about a proposed settlement of several shareholder lawsuits. It’s not a typical business update; it's about resolving legal battles *against the company's own leaders*. The main docum
SEC filings
All filings →Insider trades
All insider trades →Exicure, Inc. has no reported insider trades in the last 90 days.